Interaction of four methylxanthine compounds and norepinephrine on cardiac phosphorylase activation and cardiac contractility.
D015105:3',5'-Cyclic-AMP Phosphodiesterases / Q000037:antagonists & inhibitors*; D000818:Animals; D002110:Caffeine / Q000494:pharmacology; D004305:Dose-Response Relationship, Drug; D004357:Drug Synergism; D004789:Enzyme Activation; D005260:Female; D006168:Guinea Pigs; D008297:Male; D009200:Myocardial Contraction / Q000187:drug effects*; D009206:Myocardium / Q000201:enzymology; D009538:Nicotine / Q000494:pharmacology; D009638:Norepinephrine / Q000494:pharmacology*; D010208:Papaverine / Q000494:pharmacology; D010726:Phosphodiesterase Inhibitors; D006005:Phosphorylases / Q000378:metabolism*; D013329:Structure-Activity Relationship; D013805:Theobromine / Q000494:pharmacology; D013806:Theophylline / Q000494:pharmacology; D014970:Xanthines / Q000494:pharmacology*
D010726:Phosphodiesterase Inhibitors; D014970:Xanthines; D002110:Caffeine; D009538:Nicotine; D013806:Theophylline; D010208:Papaverine; D006005:Phosphorylases; D015105:3',5'-Cyclic-AMP Phosphodiesterases; D013805:Theobromine; D009638:Norepinephrine